Background: Solar urticaria is a rare photodermatosis which often begins from the third to the fifth decade. Usual treatment consists of photoprotection measures and antihistamines although disease control is sometimes unsatisfactory with both. We report herein a very severe case of solar urticaria we treated with intravenous immunoglobulins.
Case-report: A 55-year-old woman suffered for 3 years from very severe solar urticaria which resisted treatment. Phototests revealed two action spectra: the first in UVA near 380 nm with a minimal urticarian dose of 0.025 J/cm(2), the second near 500 nm in visible light.
Results: As last resort treatment, we gave our patient intravenous immunoglobulins. After the third course of treatment, the improvement was impressive as the patient could tolerate visible light and 15 minutes of intense solar exposure. The minimal urticarian dose was raised from 0.025 J/cm(2) to 27 J/cm(2) in UVA. One year after treatment, the solar urticaria has disappeared.
Conclusions: We report herein the first case of solar urticaria treated with success with immunoglobulin. Intravenous immunoglobulin treatment is well for its effectiveness in many autoimmune diseases such as autoimmune thrombocytopenic purpura, and also, as recently proven, in some cases of severe idiopathic chronic urticaria.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A case of solar urticaria complicated by eosinophilic granulomatosis with polyangiitis treated with mepolizumab.
J Dermatol
September 2024
Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
New insights into chronic inducible urticaria.
Curr Allergy Asthma Rep
August 2024
Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, 10178, Berlin, Germany.
Article Synopsis
- Chronic inducible urticaria (CIndU) is a difficult-to-manage condition marked by recurring hives and swelling, triggered by specific factors, and recent research has focused on understanding its causes and improving treatment options.
- New methods for evaluating patient experiences have been developed, highlighting the significant impact CIndU has on quality of life and enabling better diagnosis through provocation tests for different subtypes.
- Currently, second-generation non-sedating antihistamines are the primary recommended treatment, but they often fall short; however, off-label use of omalizumab shows promise, along with other emerging therapies being researched for future options.
A case of solar urticaria with inhibition spectrum in ultraviolet radiation A and visible light successfully treated by ultraviolet radiation A rush hardening therapy.
J Dermatol
July 2024
Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan.
Chronic Inducible Urticaria.
Immunol Allergy Clin North Am
August 2024
Department of Dermatology and Venerology, Kepler University Hospital, Urticaria Center of Excellence and Reference (UCARE), Linz, Austria; Center for medical research, Johannes Kepler University, Linz, Austria; Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany. Electronic address:
Article Synopsis
- * Diagnosis relies on patient history, trigger tests, and self-reported symptoms.
- * Current treatments mirror those for chronic spontaneous urticaria but are largely off-label; new targeted therapies are in clinical trials due to the significant impact on patients.
Successful serial plasmapheresis for solar urticaria, a case report and literature review.
J Dermatolog Treat
December 2024
Photodermatology Unit, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Article Synopsis
- The study highlights the effectiveness of traditional therapeutic plasmapheresis (TPE) as a treatment for difficult cases of solar urticaria (SU) that don't respond to common medications.* -
- A specific case involving a patient who underwent 42 TPE procedures over five years showed significant improvement in their condition, as indicated by increased resistance to UV light during testing after treatment.* -
- The research also compares the outcomes of this case with previous studies on TPE for SU, showing that patients with positive intradermal tests generally benefited more from TPE, although some relapsed in a short time.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!